




It's the time of year for everyone to post their forecasts for 2026. Usually, we forget about these until about March when everyone starts making revisions. So rather than participate in this traditional investment rite, we prefer to think about themes and how they may or may not play out during the whole of the year.

The investment hype of AI will switch from chip processing power to the business effectiveness of the use of Al. Over the last 3 years (since ChatGPT day) the focus has been on Al infrastructure, Al software and Al large language models. We expect this focus will shift from who gives us AI, to who uses AI. This will become particularly pertinent in those sectors where AI use will make a demonstrable financial difference. We already note the use of AI to solve the cost and efficiency challenges of pharmaceutical research and development. Dashboards such as Insilico Medicine will become the landing page for pharma and biotech rather than traditional (oldfashioned?) lifestyle images.



Insilico Medicine








We note the rally in biotech stocks in recent months and the outperformance relative to AI and robotics and the

broader market overall.


Chart 11: From AI to BioTech



US tariffs will be an enabler for capital formation in the emerging markets. Those EM markets that, before tariffs, traded on labor cost advantages to produce cheap goods with little or no IP (t-shirts), will now be motivated to create actual equity added value in their domestic production with a renewed focus on capital goods.

The initial global reaction to US tariffs can be summarised as representing "a significant risk" to the global economy (Kristalina Georgieva, April 2025). Since then, views have moderated reflecting both the tempering of actual tariff rates and the fact that exporters have adjusted their business model; most emerging economies can "weather US tariffs without excessive pain" (Maplecroft, November 2025).

Chart 22: Tariffs




Certainly, investor reaction in those countries deemed to be particularly exposed to US tariffs has generated

<sup>&</sup>lt;sup>1</sup>Bloomberg, GIB Asset Management

<sup>&</sup>lt;sup>2</sup>GIB Asset Management

robust returns relative to the overall global market.


Chart 32: Frontier markets and liberations day



For more on the potential broadening of investor appetite for EM, read here.


US corporate gross margins will continue to be able to absorb tariffs without passing them on to consumers in the form of capital goods inflation. US corporate gross margins have continued to expand across all cap categories (large cap, small cap and tech cap) and consensus forecasts suggest this will continue. Such gross margin resilience supports supply chain pricing power creating capacity for continued tariff-exposure inflation absorption.

Chart 43: Gross margin



The components of core CPI inflation reflective of tariffs (core goods, food and energy) remained zero to negative for most of 2025.

Chart 53: CPI core components



While these components merit a watchful eye, the combination of resilient gross margins and a businessfriendly US administration inclined to be responsive to exemption requests, suggest muted inflation risk in the near term.

It will not be different in Europe this time. European entrepreneurship is mired in the DNA of European society and strong social safety nets will continue to have the opposite effect of the intent by effectively encouraging young ambitious Europeans to move to Dubai and the broader Gulf region.

In the first half of 2025, there was much optimistic commentary that Europe would emerge with stronger economic growth on the back of easing energy prices and recovering household finances. In Germany in particular, there was an expectation of growth boosted by public sector investments in defense and infrastructure and much greater fiscal policy space. The reality, again, fell short of initial expectations; the initial rally of German equities against US equities only lasted the first half of the year with significant performance rotation back to the US at the time of writing.

Chart 63: German/US rotation




<sup>3</sup>Bloomberg



The harsh reality is that Europe cannot get out of its own way. The hopeful tone of the October 2024 Draghi report with its 383 recommendations for improved European competitiveness hit the brick wall of European bureaucracy with only 42 of the recommendations implemented a year later. The only way it can be different in Germany (and Germany is key to greater European performance) is a fundamental restructuring of economic society. Home ownership (the most basic component of equity wealth creation) is lower in Germany than the rest of Europe and much lower than in the US. No surprise then that new business formation relative to economic size and population lags miles behind the United States.

Chart 74: Home ownership vs new businesses



Difficult to see the 6,700 or so European millionaire migrants to Dubai in 2024 returning home any time soon.

It will be different in Japan this time. The history of Japan's various stimulus packages is a story of failure. The failure of the five stimulus packages from 1992 to 1999 caused the period to be known as the lost decade. Spending on public works and cash payouts simply did not reenergise what was then the second largest global economy. In 2026, expect global investors to learn a new word "Sanaenomics". These new fiscal and governance policies of the Sanae Takaichi administration are directed at the private sector that gainfully employs and pays Japanese consumers. Those employees are working longer (retirement age now at 65) and getting paid more. The second new word for global investors is "Rengo", Japan's largest trade union organisation, which is calling for a minimum 5% wage rise for 2026.

Chart 85: More money to spend



These reforms are designed to improve consumer confidence such that the Japanese propensity to consume actually has a chance to continue its recent positive momentum.

Chart 95: Propensity to consume



Sanaenomics is the reminder that trying the same remedy for the same disease and expecting a different outcome is insanity. Trying something new has better odds. For example, the elimination of decades-old cross-shareholdings will finally allow Japanese corporates to be economically rational and focus on things like shareholder value rather than inter-corporate goodwill.


Middle East Vision plans will morph from ambition to pragmatism and unlock substantial FDI. Saudi Vision 2030 will be 10 years' old in 2026. While Western media headlines will undoubtedly continue to focus on the progress or otherwise of a handful of mega projects, the reality is that Saudi Arabia specifically, and the Gulf more generally, has utterly transformed its domestic economy away from total reliance on the state to an ecosystem of thousands of young entrepreneurs (both male and female)

<sup>&</sup>lt;sup>4</sup>World Bank, GIB Asset Management

<sup>&</sup>lt;sup>5</sup>Ministry of Health, Labour and Welfare


eager to participate in Saudi economic activity.

Chart 106: Gross fixed capital formation - Private sector % of GDP



During 2026, this momentum means the Gulf States Vision plans will move to their implementation phase becoming investible projects attracting hundreds of small and medium sized niche companies.

Chart 117: New commercial registrations



This economic transformation provides a diverse operating and investment environment that moves the region away from a select handful of mega joint ventures with stateowned actors to an entrepreneurial framework capable of attracting global FDI in all shapes and sizes.

The SRT market will grow such that bank originated loans will fuel growth of the private credit market in the **US and beyond.** As regulators continue to lag the speed of bank deregulation relative to speed of demand for bank credit, banks turn to the SRT market for risk capital relief. This has been the case since 2023 when the Federal Reserve finally approved the use of SRT's for US banks for risk weighted capital relief.


Thus, the impetus for market changing growth can be expected to come from the US while Europe will remain an important market.

Chart 128: SRT transactions



This of course is happening at the same time that the private credit market (the major buyer of SRTs) is turning the US bank market on its head.

Chart 139: Commercial and Industrial bank loans vs Private credit AUM



On the assumption that bank originated loans are subject to greater credit committee scrutiny and diligence than by their private credit portfolio manager counterparts, we should expect the SRT market to accelerate the fueling of the private credit market. This will provide credit quality assurances for private credit investors looking for enhanced yield and longer duration. Banks are not yet redundant, but this structural change will lead to originate to distribute models and a focus on other revenue sources away from credit spreads. Bank regulators will increasingly need to understand retained (residual) risk and warehousing risk, something that was not well understood prior to the GFC. During 2026 central banks and regulators will increasingly need to balance political demands for credit led stimulus and bank system stability in a context where moral hazard isn't a thing in the private credit markets.

<sup>&</sup>lt;sup>6</sup>World Bank

<sup>&</sup>lt;sup>7</sup>Ministry of Commerce

<sup>8</sup>IMF 9FRED

Views, opinions, statements, forecasts and projections are as of date and subject to change without prior notice. There is no guarantee they will be met.



This document is not for distribution to retail clients and is directed exclusively at GIB Asset Management's professional clients, institutional clients and/or Qualified Persons. This document has been prepared by Gulf International Bank (UK) Limited ("GIB (UK)"), trading as GIB Asset Management for discussion purposes only with the intended recipient. GIB UK is authorised by the Prudential Regulation Authority ("PRA") and regulated by the Financial Conduct Authority and PRA. GIB UK is registered as an Investment Adviser with the Securities and Exchange Commission in the United States. The document shows market commentary and does not constitute investment research.

This document is provided for information purposes and is intended for your use only and does not constitute an invitation or offer to subscribe for or purchase any of the products or services mentioned. The information provided is not intended to provide a sufficient basis on which to make an investment decision and is not a personal recommendation. The portfolio will exclude stocks with revenue derived from prohibited activities, e.g. alcohol production or controversial weapons. It will also exclude based on international standards, such as UN Global Compact or any environmental, social, and governance controversies, e.g. an oil spill or data privacy scandal of a company. Exclusions can be tailored to meet the needs of our clients.

Observations and views of GIB UK may change at any time without notice. Information and opinions presented in this document have been obtained or derived from sources believed by GIB UK to be reliable, but GIB UK makes no representation as to their accuracy or completeness. GIB UK accepts no liability for loss arising from the use of this document. Moreover, any investment or service to which this document may relate will not be made available by GIB UK to retail customers.

The price and value of investments mentioned and any income that might accrue could fall or rise or fluctuate. Past performance is not a guide to future performance. If an investment is denominated in a currency other than your base currency, changes in the rate of exchange may have an adverse effect on value, price or income. Nothing in any document constitutes investment, legal, accounting or tax advice, or a representation that any investment or strategy is suitable or appropriate to individual circumstances, or otherwise constitutes a personal recommendation to any specific investor unless clearly stated. The registered address of GIB UK is First Floor, One Curzon Street, W1J 5HD.

## Contact

info@gibam.com

T: +44 (0) 20 7259 3456

Follow us: in

Strategy performance. The hypothetical strategy results are based on the following assumptions: The strategy does not include deductions for brokerage commissions, fees or other charges. The simulation assumes that prices are not influenced by the hypothetical trades. The simulation assumes that purchase and sale prices are believed to be attainable. In actual trading, the prices attained may or may not be the same as the assumed orders. The strategy results do not take into account any tax implications arising from the sale or purchase of securities, which otherwise may have an impact on the gains and losses presented.